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T-cell receptor (TCR) allorecognition is often presumed to be relatively
nonspecific, attributable to either a TCR focus on exposed major
histocompatibility complex (MHC) polymorphisms or the degener-
ate recognition of allopeptides. However, paradoxically, alloreac-
tivity can proceed with high peptide and MHC specificity. Although
the underlying mechanisms remain unclear, the existence of highly
specific alloreactive TCRs has led to their use as immunotherapeutics
that can circumvent central tolerance and limit graft-versus-host
disease. Here, we show how an alloreactive TCR achieves peptide
and MHC specificity. The HCV1406 TCR was cloned from T cells that
expanded when a hepatitis C virus (HCV)-infected HLA-A2− individ-
ual received an HLA-A2+ liver allograft. HCV1406 was subsequently
shown to recognize the HCV nonstructural protein 3 (NS3):1406–
1415 epitope with high specificity when presented by HLA-A2. We
show that NS3/HLA-A2 recognition by the HCV1406 TCR is critically
dependent on features unique to both the allo-MHC and the
NS3 epitope. We also find cooperativity between structural mim-
icry and a crucial peptide “hot spot” and demonstrate its role,
along with the MHC, in directing the specificity of allorecognition.
Our results help explain the paradox of specificity in alloreactive
TCRs and have implications for their use in immunotherapy and
related efforts to manipulate TCR recognition, as well as alloreac-
tivity in general.
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T-cell receptor (TCR) recognition of peptides bound andpresented by proteins encoded by the major histocompati-
bility complex (MHC) underlies specificity in cellular immunity.
The MHC locus is the most polymorphic region in the human
genome, leading to many thousands of expressed MHC variants.
Of these MHC variants, any one individual can express, at most,
six class I and six class II proteins. Selection processes during thymic
education result in a TCR repertoire tolerant of self-peptides pre-
sented by self-MHC, as evidenced by the strong immune responses
associated with transplantation of tissues with donor/recipient
MHC mismatches (alloreactivity). Indeed, precursor frequencies
for alloreactive T cells are up to 1,000-fold higher than frequencies
for T cells that respond to self-MHC (1). Alloreactive T-cell responses
contribute to the significant morbidity associated with rejection
of transplanted tissues and graft-versus-host disease.
Surprisingly, many alloreactive T cells display a degree of
specificity reflective of traditional syngeneic T cells (2), a coun-
terintuitive finding, given the prevailing theories that alloreactivity
is driven by TCR “misfocusing” on non–self-MHC polymorphisms
(MHC-centric) or the recognition of a repertoire of unique allo-
peptides (peptide-centric) (3). Although this enigma has not been
fully explained, it has nonetheless led to a growing interest in the
use of such “allospecific” TCRs in immunotherapy. Central tol-
erance mechanisms exist to avoid self-reactivity, hindering the
identification of highly avid T cells specific for shared (nonmutated)
tumor antigens. The phenomenon of specificity in alloreactivity
has thus been exploited to identify T cells capable of recognizing
shared tumor antigens with high potency, using antigen-specific
T cells from mismatched donors to circumvent tolerance (4, 5).
In a related fashion, antigen-specific alloreactive T cells have been
used to target conditions such as posttransplantation Epstein–Barr
virus-associated lymphoma (6, 7).
Several studies have examined the structural features of allo-
geneic TCR–pMHC complexes (8–11). An overall assessment of
these structures is that rather than demonstrating features that
are clearly characteristic of alloreactivity, they illustrate features
similar to traditional syngeneic complexes of TCRs with peptides
presented by self-MHC (3, 12, 13). The LC13 TCR, for example,
was recently shown to engage allo- and self-MHC almost iden-
tically, and could distinguish between closely related class I al-
leles (14, 15). In that case, recognition of an allopeptide occurred
via conformational changes that bring it into a conformation
mimicking a viral peptide, thus demonstrating the importance of
both the MHC and peptide. A recent study of an alloreactive
TCR that specifically recognizes an antigen from Hodgkin’s
lymphoma concluded that MHC polymorphisms likely determine
a unique peptide-binding mode, contributing to high peptide
specificity (16). It is clear from these and other studies that specific
allorecognition requires elements of the composite peptide-MHC
ligand, with the potential for both to influence specificity.
Significance
T-cell alloreactivity drives transplant rejection. Alloreactive
recognition is believed to proceed with limited specificity, ac-
counting for the high numbers of alloreactive T cells in humans.
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how a T-cell receptor (TCR) achieves high specificity toward a
peptide antigen presented by allo-major histocompatibility
complex (MHC). Counter to prevailing theories of alloreactivity,
we find that TCR recognition is driven by a cooperative in-
terplay between features unique to both the allo-MHC and the
peptide, such that binding is both MHC- and peptide-centric.
Our results have broad implications for the determinants of
immune recognition and efforts in immunotherapy.
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To gain further insight into the paradoxical nature of antigen-
specific alloreactivity, we examined an alloreactive human TCR
highly specific for the nonstructural protein 3 (NS3):1406–1415
epitope from the hepatitis C virus (HCV) presented by HLA-A2.
The HCV1406 TCR was cloned from T cells that expanded when an
HCV-infected HLA-A3/A30 individual received an HLA-A2/A24 liver
allograft. HLA-A2 and A3/A30 belong to different class I MHC
supertypes (17, 18), and A2 has surface properties distinct from
HLA-B, HLA-C, nonclassical class I, and the class II proteins.
Expression of HCV1406 confers anti-HCV reactivity onto other
effector cells, which specifically recognize NS3/HLA-A2 targets in-
dependent of the CD8 coreceptor and do not recognize irrelevant
targets presented by A2 or other class I MHC proteins (19–22).
In conflict with prevailing theories of T-cell alloreactivity, we
show that the specific recognition of NS3/HLA-A2 by HCV1406
is dependent upon three intertwined components: the unique
TCR contact surface of A2, including polymorphisms that dis-
tinguish it from the other MHC proteins present in the host; the
impact of A2 polymorphisms on NS3 peptide binding and con-
formation; and unique structural and chemical features of the
NS3 peptide. Thus, HCV1406 recognition is neither MHC- nor
peptide-specific, but is both, emerging from a cooperative interplay
of features of the composite peptide-MHC ligand. Our results help
explain the paradox of antigen specificity in alloreactivity and have
implications for the use of allospecific TCRs in immunotherapy
and related efforts to manipulate TCR recognition.
Results
Fine Specificity of the HCV1406 TCR. To help understand the spec-
ificity of the HCV1406 TCR and identify the key residues in the
NS3 epitope (sequence KLVALGINAV), we performed a mu-
tational scan of the peptide. We assessed the reactivity of
HCV1406 TCR-expressing T cells by cytokine secretion when
cocultured with HLA-A2+ (referred to as A2) T2 cells pulsed
with native NS3:1406–1415 peptide or variants with substitutions
at positions 1 through 10. We evaluated the reactivity of TCR-
transduced T cells from two normal human donors as well as
TCR-transduced CD8+ or CD8-Jurkat E6.1 cells.
The data from the various cell types displayed similar patterns
of reactivity (Fig. 1 A and B), with no recognition of nonpeptide-
pulsed targets or targets pulsed with the irrelevant tyrosinase:368–
376 peptide (sequence YMDGTMSQV). As found previously
(19, 20, 22), the TCR specifically recognized NS3/A2 in a CD8-
independent manner. Modifications to the peptide had various
effects, with alanine substitutions at p1 (Lys) and p6 (Gly) proving
the most disruptive. Modification of the leucine at p5 had an in-
termediate effect, whereas modifications toward the C-terminal
end (p8 Asn, p9 Ala, and p10 Val) had little to no impact on rec-
ognition. In the experiments with Jurkat cells, the presence of CD8
led to stronger responses as generally anticipated.
To supplement the functional data, we measured the affinity
of the HCV1406 TCR toward NS3/A2 in direct binding experi-
ments using surface plasmon resonance (SPR). The TCR bound
NS3/A2 with an affinity (Kd) of 16 ± 1 μM (Fig. 1C), which is in
the range of other TCRs known to be CD8-independent (23). No
binding was again observed with the irrelevant tyrosinase pep-
tide. The affinity to the p1 Lys→Ala (K1A) NS3 variant was
measured as ≥170 μM. The large reduction in binding affinity,
amounting to a ΔΔG° of ≥1.4 kcal/mol, is consistent with the loss
of recognition in the functional experiments. Replacement of the
p1 Lys with alanine did not weaken binding of the peptide to A2,
as the A2 complexes with both the native NS3 epitope and the
K1A variant had identical melting temperatures (Tm values) of
64 °C when measured by differential scanning fluorimetry (DSF)
(Fig. 1D), reflective of high-affinity peptide binding (24).
The HCV1406 TCR Binds NS3/HLA-A2 with a Traditional Binding Mode.
We determined the structure of the complex between the
HCV1406 TCR and the NS3 peptide presented by A2 at a res-
olution of 2.5 Å (Table 1). The complex crystallized in space
group P3121 with two complexes in the asymmetrical unit. Clear
electron density was observed for the TCR–pMHC interfaces in
both complexes (Fig. S1). The two complexes were essentially
identical: All atoms of the peptides superimposed with an rmsd
of 0.8 Å, the A2 backbones superimposed with an rmsd of 0.7 Å,
and the TCR backbones superimposed with an rmsd of 0.5 Å.
The TCR adopts a typical diagonal orientation over the pMHC,
binding directly over the peptide-binding groove with a crossing
angle of 30° (Fig. 2 A and B). The incident angle (or tilt, defined
as the angle between the plane of the MHC peptide-binding
groove and a vertical line down the Vα/Vβ pseudosymmetry
axis) is 17°. This combination of crossing and incident angles
places the docking geometry of HCV1406 near the edge of what
has been observed for other A2-binding TCRs (Fig. 2C). How-
ever, similar binding angles have been observed with other TCRs
(25), and considered alongside the larger set of all human and
mice complexes with class I or class II MHC, the binding ge-
ometry of HCV1406 is well within what has been observed for
functioning TCRs (Fig. S2). The nondistinctive geometry is
particularly clear when it is considered alongside TCRs that bind
with “reverse polarity” (26, 27) and the nonsignaling 42F3 TCR
in complex with the p3A1 ligand (28). As a further demonstration
of its traditional binding geometry, the binding of HCV1046 to
NS3/A2 was not distinctive when the position of the center of
mass of the Vα/Vβ domains over A2 was compared with other A2-
binding receptors (Fig. 2D). Although HCV1406 recognition of
NS3/A2 is CD8-independent, the binding geometry is compatible
with CD8 binding, because naturally occurring NS3 variants require
CD8 for efficient recognition by HCV1406-transduced T cells (20),
and as shown in Fig. 1B, the presence of CD8 strengthened the
responses to single-amino acid NS3 variants.
A total of 2,049 Å2 of solvent accessible surface area is buried
in the TCR–pMHC interface, with 54% contributed by Vα and
46% by Vβ. The TCR buries 345 Å2 of peptide surface area, or

















































































































NS3 K1ATm = 63.5 ± 0.2

























Fig. 1. Fine specificity of the HCV1406 TCR with the NS3 antigen presented
by HLA-A2. (A) Cytokine (IFN-γ) release measured with transduced bulk
T cells from two donors recognizing peptide-pulsed T2 cells. No response was
observed with no peptide or with the irrelevant tyrosinase peptide, whereas
strong responses were observed with the native NS3 epitope. Mutations that
significantly impacted recognition were K1A and G6A. (B) Cytokine (IL-2)
release measured with Jurkat E6.1 cells without CD8 or cotransduced with
CD8. The response patterns closely resemble the response patterns with the
donor-derived T cells in A. (C) Direct binding of the HCV1406 TCR to NS3/A2
measured by SPR. Binding of the TCR to the native epitope yielded a Kd
value of 16 ± 1 μM. Consistent with the functional data, the K1A substitution
substantially weakened binding (Kd ≥ 170 μM), and no binding was detected
with the irrelevant tyrosinase peptide. RU, resonance units. (D) NS3 peptide
binds to A2 with high affinity as measured by DSF (Tm = 63.5 °C). Substitution of
the p1 Lys with Ala did not weaken peptide binding (note the y axis is shifted by+4
units for the K1A data to facilitate comparison with the native peptide data).



























The complementarity-determining region (CDR) loops are
arranged over the pMHC as commonly observed, with the
hypervariable CDR3α/CDR3β loops over the center of the
peptide; the CDR1α and CDR1β loops over the peptide N- and
C-terminal regions, respectively; and the CDR2α and CDR2β
loops over the α2 and α1 helices, respectively (Fig. 2B). Using a
cutoff distance of 4 Å, there are 134 interatomic contacts in the
interface, of which 54 are between the TCR and the peptide and
80 are between the TCR and A2.
HCV1406 Engagement of the NS3 Peptide. The HCV1406 TCR
engages the NS3 peptide along its entire length, although with
greater participation of the N-terminal half and the TCR α-chain
(Fig. 3 A and B). The protruding side chains of the peptide are
the lysine at p1, the leucine at p5, and the asparagine at p8. The
p1 Lys is engaged by Ser33 and Glu34 of CDR1α, which form
hydrogen bonds and a salt-bridge with the lysine side chain. The
p5 Leu fits into a large hydrophobic cleft formed by residues in
CDR1α, CDR3α, and CDR3β. The p8 Asn forms only two
contacts with CDR3β. Other contacts are hydrogen bonds made
to the peptide backbone at p6 and p7 by Asp102 of CDR3α.
The structural data allow a more detailed interpretation of the
specificity and binding experiments shown in Fig. 1. The electrostatic
interactions with p1 Lys are clearly crucial for recognition, given that
substitution of p1 Lys with alanine is the most detrimental peptide
modification studied. The loose accommodation of the p5 Leu side
chain in the hydrophobic cleft is consistent with the more moderate
impact the p5 Leu→Ala substitution has on recognition. The TCR’s
structural bias toward the N-terminal half of the peptide is consis-
tent with the minor impacts of substitutions at positions 8–10 in
recognition. The disruption from substitution of the alanine at p6 Gly
is attributable to tight packing between the side of the peptide and
residues of the A2 α2-helix, such that mutation of p6 Gly to anything
other than alanine is likely to influence peptide conformation.
Table 1. X-ray data collection and refinement statistics
Data collection
Resolution, Å 37.2–2.50 (2.6–2.5)
Space group P 31 2 1
Cell dimensions
a, b, c; Å 128.8, 128.8, 223.6
α, β, γ; ° 90.0, 90.0, 120.0
Unique reflections* 74,525 (7,352)
Rmerge 0.23 (0.7)
<I/σ(I)> 9.1 (2.9)






No. of protein atoms 13,339
Rmsd from ideality
Bond lengths, Å 0.015









PDB ID code 5JZI
*Values in parentheses are statistics of the highest resolution shell.
†Rfree is calculated for a randomly selected 5.0% of reflections not included
in refinement.
Fig. 2. Overview of the HCV1406–NS3/A2 complex. (A) Structural overview
showing the position of the TCR variable domains relative to the pMHC.
(B) Position of the CDR3 loops over the A2 molecule. (C) Incident vs. crossing
angles for TCRs that bind A2. HCV1406 binds NS3/A2 near the edge as in-
dicated by the red circle, but the docking geometry is within the limits of
what has been observed with other receptors (also Fig. S2). (D) Positions of
the centers of mass of the Vα/Vβ domains of the A2-binding TCRs in C over
the A2 center of mass, with the center of mass of HCV1406 shown in red.
E4794 | www.pnas.org/cgi/doi/10.1073/pnas.1700459114 Wang et al.
Comparing the peptide in the TCR–pMHC complex with the
peptide in the unbound NS3/A2 (PDB ID 3MRM) complex in-
dicates that there are no major alterations to peptide confor-
mation upon TCR binding. Interestingly, however, the latter
portion of the peptide is “lifted” from the binding groove by 1–1.5 Å
upon TCR binding, beginning at p4 Ala and continuing through the
C-terminal valine at p10 (Fig. 3C). Peptide lifting is not attributable
to weak peptide binding to the MHC, because NS3 binds strongly
to A2 as shown above. It may reflect the weaker participation of the
β-chain in engaging the peptide, perhaps coupled with weaker in-
teractions of peptides with class I MHC proteins at their C-terminal
ends (29).
HCV1406 Engagement of HLA-A2. Although peptide engagement is
biased toward the N-terminal half as discussed above, the HCV1406
TCR binds the A2 protein centrally, making contacts along the
α1- and α2-helices. On the α1-helix, salt-bridges from Glu34 in
CDR1α and Glu101 in CDR3α neutralize the positively charged
cluster of Arg65 and Lys66 (Fig. 4 A and C). The Arg65/Lys66
combination is essentially exclusive to A2, and the engagement
of this region via electrostatic interactions from CDR1α and CDR3α
is a distinctive feature of TCRs that bind A2, influencing the position
of the TCR as well as the composition of TCR loops (30).
Further down the α1-helix, the region from Ala69 to Val76 is
contacted by CDR2β, whose hairpin structure runs almost par-
allel to the helix (Fig. 4 B and C). Tyr50 of CDR2β is aligned
alongside the helix as commonly observed in many TCR–pMHC
complexes (31), contacting Ala69 and Gln72. Glu56β forms a
salt-bridge with Arg75, an interaction less frequently observed in
TCR complexes but present in several structures of TCRs with
A2 (30).
Contacts to the α2-helix are more distributed among the TCR-
binding loops, with residues in CDR1α, CDR2α, CDR1β, and
CDR3β all engaging a span of the helix that ranges from Lys146
in the short arm to Thr163 in the long arm (Fig. 4 D and E).
There are multiple electrostatic interactions between the TCR
and the length of the α2-helix. These interactions include a salt-
bridge from Asp30 of CDR1β to Lys146, which is also observed
in other complexes with A2 (30). Another salt-bridge is formed
between Lys60 of CDR2α and Glu154, and hydrogen bonds are
made to Ala149 and Thr163 from residues in CDR3β and CDR1α,
respectively.
Structural Features of Allorecognition: Recognition Is Dependent on
Surface Features that Distinguish A2 from Other MHC Proteins in the
Host.Although it recognizes NS3 presented by A2, the HCV1406
TCR developed in a host that was HLA-A2−. To gain more in-
sight into the basis for allorecognition of HLA-A2 by HCV1406,
we compared the sequences of A2 with the sequences of other
class I HLA proteins, emphasizing those amino acids that were
contacted by the TCR or otherwise likely to influence receptor
binding. Our goal was to isolate any distinctive features of
A2 compared with host class I molecules on which HCV1406
may have been positively selected or otherwise engaged during
the course of its normal biology, and then to ascertain the extent
to which the TCR relied upon these A2-distinctive features for
binding. We also assessed the importance of these positions on
the peptide–MHC interaction.
We first compared A2 with the classical class I MHC proteins
of the allograft recipient, which were typed as A3/A30 and B7/
B13 for HLA-A and HLA-B. The HLA-C genes in the host were
not recorded, but the C family is less polymorphic and we were
able to assess all known C types. Fifty polymorphic sites in hu-
man class I MHC proteins are found in the peptide-binding
domain. For the A, B, and C alleles, 16 of these alleles are in the
α1-helix and seven are in the α2-helix. Most of the polymorphic
sites are outside of the contact zone of the TCR. Nonetheless,
after examining the sequences in the context of the structure, it
was clear that the binding of the HCV1406 TCR is directly
influenced by sites that distinguish A2 from the other class I MHC
proteins.
The clearest influences of A2 polymorphic sites were seen on
the more polymorphic α1-helix (Fig. 5A). Position 62 is a glycine
in A2, but a glutamine or arginine in the other A and B proteins
Fig. 3. Engagement of NS3 peptide by HCV1406. (A) Key contacts to the peptide
from the loops of the Vα and Vβ domains. The side chain of p1 Lys forms a hy-
drogen bond with Ser33 and a salt-bridge with Glu34 of CDR1α. The side chain of
p5 Leu is accommodated by a hydrophobic cleft formed by CDR1α, CDR2α, and
CDR3β. Hydrogen bonds are formed to the backbone at positions 6 and 7 by
Asp102 of CDR3α. The side chain of p8 Asn is at the edge of the interface,
interacting minimally with CDR3β. (B) Schematic showing TCR contacts to peptide
amino acids by the participating CDR loops. The width of the black lines is pro-
portional to the number of contacts, as indicated by the numbers above each line.
(C) Comparison of the conformation of the NS3 peptide in the A2-binding groove
in the TCR-bound and TCR-free structures. When bound to the TCR, the peptide is
“lifted” by ∼1 Å, beginning at position 4 and continuing to the C terminus.



























and in >99% of the C proteins. HCV1406 does not directly
contact Gly62, but the position is buried by the CDR1α loop in
the structure of the complex, such that a glutamine or arginine
would clash with Ser33α and Glu34α (Fig. 5B). Substitution of
Gly62 with glutamine or arginine weakened the binding of
HCV1406 to NS3/A2 between six- and 10-fold as measured by
SPR (Fig. 5A and Table 2; data in Fig. S3).
Further down the α1-helix, Arg65 and Lys66 form the cluster
of positive charge that is almost exclusive to A2 and helps orient
A2-binding TCRs on the MHC (30). Arg65 is glutamine in the B
proteins and in >99% of the C proteins, and Lys66 is asparagine
in the other A proteins and isoleucine in the B proteins. In the
HCV1406 structure, Arg65 forms salt-bridges with Glu101 of
CDR3α and Glu34 of CDR1α, and Lys66 forms a salt-bridge
with Glu34α (Fig. 5C). Modeling glutamine in for Arg65 or
asparagine/isoleucine in for Lys66 did not introduce any inter-
atomic clashes, but these replacements would disrupt the net-
work of electrostatic interactions linking the TCR and its ligand.
Substitution of Arg65 with the glutamine found in the B or C
proteins had a dramatic impact on TCR binding, leading to
undetectable binding (Table 2). Similar results were obtained
when Lys66 was substituted with the asparagine found in A3/
A30 or the isoleucine found in B7/B13. The R65Q/K66I double
mutation also led to undetectable binding.
Other amino acids that are at least partially distinctive to
A2 and are involved in the HCV1406 interface are Ala69, Val76,
and Gly79. Position 69 is arginine in the C proteins, position 76 is
glutamate in the B7/B13 proteins, and position 79 is arginine in
the B7/B13 and C proteins. Mutations at these positions would
introduce clashes (A69R), charge repulsion (V76E), or both (G79R)
(Fig. 5 D–F). As predicted, mutations at these sites also had dis-
ruptive effects on TCR binding (Fig. 5A and Table 2).
We identified rare variants of the A, B, and C proteins that
had some of the surface features noted above (i.e., C*02:66 has
the R65/K66 pair), but none had all. We also examined the less
polymorphic nonclassical class I MHC proteins, and found that
HCV1406 interacts with elements of the A2 surface that distin-
guish it from these rare variants as well. For example, variants of
the nonclassical class I molecules HLA-E, HLA-F, and HLA-G
lack glycines at positions 62 and 79 and the positive charge
cluster of Arg65/Lys66 (Fig. 5A).
Although the TCR clearly interacted with sites that are dis-
tinctive to A2, it did not show preferential engagement of poly-
morphic sites at the expense of others, because nonpolymorphic
sites made significant contacts, as shown in Fig. 4 (major non-
polymorphic contact sites include Gln72 on the α1-helix and the
stretch of Glu154 to Tyr159 on the α2-helix). Moreover, other
polymorphic sites did not seem to play a direct role in TCR binding.
One example is position 151 on the α2-helix. Position 151 is a
histidine in A2, but an arginine in A30 and the B/C proteins. In the
structure of the HCV1406 complex, there are contacts between the
His151 side chain and the ring of Tyr98 of CDR3β (Fig. 5G).
Modeling arginine in the place of His151 would not remove these
contacts, or introduce any other clashes. Consistent with the
structure, mutation of His151 to arginine had no discernable impact
on TCR binding (Table 2 and Fig. S3).
We also compared the sequence of A2 with class II MHC
sequences because it is possible that T cells expressing HCV1406
were positively selected on a class II protein. Although class I
and class II proteins are structurally homologous, they are suf-
ficiently different at a local level to conclude that A2 presents a
surface distinct from any class II MHC proteins in the host. For
example, the lengths and twists of the class I/class II peptide-
binding groove α-helices differ, as do the identity of the poly-
morphic and nonpolymorphic sites across the two helices. At a
more granular level of detail, no human class II MHC α-chains
maintain those features most distinctive to A2 at the equivalent
positions in the peptide-binding domain α-helices (e.g.,
Gly62, Arg65/Lys66).
Fig. 4. Engagement of HLA-A2 by HCV1406. (A) As seen widely in other TCR structures with A2 (30), electrostatic interactions are formed between the TCR
and N-terminal end of the A2 α1-helix. In addition to interacting with the peptide, Glu34 in CDR1α forms salt-bridges with Lys66 and Arg65. Glu101 in CDR3α
forms a salt-bridge with Arg65. (B) CDR2β docks parallel to the C-terminal end of the α1-helix. A salt-bridge is formed between Glu56β and Arg75.
(C) Schematic showing TCR contacts to the α1-helix by the participating CDR loops. The width of the black lines is proportional to the number of contacts, as
indicated by the numbers above each line. The blue circles indicate polymorphic sites. (D) Interactions between the A2 α2-helix are more distributed, involving
residues from CDR1α, CDR2α, CDR3β, and CDR1β. (E) Schematic showing TCR contacts to the α2-helix by the participating CDR loops. The width of the black
lines is proportional to the number of contacts, as indicated by the numbers above each line. The blue circles indicate polymorphic sites.
E4796 | www.pnas.org/cgi/doi/10.1073/pnas.1700459114 Wang et al.
Overall, our results confirm that binding of HCV1406 to NS3/A2 is
strongly dependent upon select polymorphic surface residues that
distinguish A2 from other MHC proteins within the host that re-
ceived the A2+ allograft. This distinction includes all known variants
of the alleles that were recorded upon transplantation (A3, A30, B7,
and B13), as well as the unrecorded HLA-C, nonclassical class I, and
class II proteins.
HLA-A2 Polymorphisms Impact Peptide Binding and Conformation
and Indirectly Influence TCR Binding. The polymorphisms assessed
above impacted receptor binding to various extents, but did not
significantly impact peptide binding as measured by DSF (Table
2). Due to their positions within the peptide-binding groove,
however, the majority of other A2 polymorphisms are expected to
impact the MHC–peptide interaction. Impacts on peptide binding
are obvious at a high level, because MHC polymorphisms dictate
amino acid preferences, particularly at the primary anchors (18).
The preferences among A2, A3, A30, B7, B13, and C alleles differ
considerably. For example, A2 prefers a small hydrophobic amino
acid, such as valine, at the peptide C terminus, whereas A3 prefers a
positively charged amino acid, such as lysine. To help quantify the
impact of the binding groove polymorphisms on peptide binding, we
assessed the binding of the NS3 peptide to the other A, B, and C
alleles using the consensus-based MHC-I–binding prediction
server from the Immune Epitope Database (32). As expected,
the NS3 peptide was predicted to be most strongly bound by A2
(Table S1).
Beyond impacting peptide binding directly, polymorphisms
within the binding groove are also likely to influence peptide
conformation, detectable as an impact on TCR-binding affinity
(33, 34). We tested influences on conformation directly by ex-
amining position 152, which is a valine in A2 and B13, but a
glutamate or tryptophan in the other A, B, C, and E proteins.
Substituting in either the glutamate or the tryptophan is pre-
dicted to influence peptide conformation through clashes with
Asn8 of the peptide (Fig. 5H). Indeed, replacing Val152 with
glutamate weakened TCR binding approximately threefold,
whereas replacing it with tryptophan led to much weaker binding
(Table 2 and Fig. S3). These outcomes are consistent with alter-
ations in peptide conformation. Of all those mutations tested,
these mutations also had the greatest impact on peptide binding to
the MHC as assessed by measurements of thermal stability (Table
2). These results confirm that in addition to impacting peptide and
TCR binding directly, A2 polymorphisms can impact TCR binding
indirectly via their influence on peptide conformation.
Cross-Reactivity with a Tumor Antigen Reveals Cooperativity
Between Structural Mimicry and a Peptide Hot Spot. In examining
the structure of the HCV1406–NS3/A2 complex, we noted that
the conformation of the NS3 peptide in the A2-binding groove is
remarkably similar to the conformation of the decameric MART-1
tumor antigen (sequence ELAGIGILTV) bound to A2 (35, 36)
(Fig. 6A). In addition to the common backbones, except for the
p1 residue, there are chemical and structural similarities in both
peptide side chains. These similarities are best shown by a su-
perimposition of the MART-1 peptide onto the NS3 peptide in
the HCV1406–NS3/A2 complex (Fig. 6B). There are no steric
clashes with the TCR or MHC, and key residues identified both
structurally and functionally show structural and chemical com-
patibility (e.g., leucine/isoleucine at p5).
In the context of the structure, the only major difference be-
tween the two peptides is the p1 Lys in NS3 vs. the p1 Glu in
MART-1. The p1 Lys forms multiple electrostatic interactions
Fig. 5. Structural features of allorecognition of HLA-A2 by HCV1406.
(A) Sequences of the α1-helix for the HLA-A2, HLA-A3, HLA-A30, HLA-B7, HLA-
B13, HLA-C, HLA-E, HLA-F, and HLA-G families. The A2 sequence is across the top;
differences from the other alleles identified via the IMGT database are noted.
Mutations designed to test the importance of A2 surface features on receptor
binding are shaded yellow, orange, or red depending on their impact on ΔΔG°
(values are provided in Table 2, and binding data are provided in Fig. S3). (B)
Substitutions to Gly62 present in A2 would result in steric clashes with Ser33 and
Glu34 of CDR1α. (C) Substitutions to the Arg65/Lys66 pair found in A2 would
perturb finely tuned electrostatic interactions with the peptide, CDR1α, and
CDR3α. (D) Substitution of Ala69 present in A2 with the arginine found in C
proteins would result in clashes and charge repulsion with Asp103 and Glu101α
of CDR3α. (E) Substitution of Val76 with the glutamate found in B7/B13 could
result in clashes and charge repulsion with Asp30 of CDR1β. (F) Substitution of
Gly79 in A2 with the arginine found in B7, B13, C, E, and F proteins could
result in clashes with Val52 and Asn53 of CDR2β. (G) Substitution of
His151 present in A2 with the arginine found in the A30, B7, B13, and C
proteins should have little impact on receptor binding. (H) Substitutions to
Val152 present in A2 would perturb the peptide–MHC interaction via clashes
with the P8 arginine.



























with the TCR (Fig. 3), and their importance is demonstrated by the
negative impact of the K1A substitution on binding and function
(Fig. 1). As shown in Fig. 6B, superimposition of the MART-1
peptide into the HCV1406–NS3/A2 complex showed charge re-
pulsion would occur between the p1 Glu of MART-1 and Glu34 of
CDR1α, with a distance between the two carboxylates of only 3.5 Å.
The structural and chemical convergence between NS3 and
MART-1, and how they fit within the interface between HCV1406
and A2, prompted us to ask if the HCV1406 TCR could recognize a
variant of the MART-1 decamer modified at the N terminus to
provide the crucial positive charge present in the NS3 peptide.
Accordingly, we examined a MART-1 peptide with p1 Glu sub-
stituted with lysine (KLAGIGILTV). In a binding experiment
with SPR, HCV1406 recognized this ligand with an affinity
threefold weaker than the affinity toward the NS3 epitope (Fig. 6C).
We saw no detectable binding with the wild-type MART-1 epitope.
We also saw no detectable binding with a variant of the negative
control tyrosinase peptide modified with a p1 Lys (KMDGTMSQV),
demonstrating the importance of the NS3/MART-1 structural con-
vergence in permitting TCR cross-reactivity. Consistent with the
binding data, the p1-modified MART-1 peptide was also recog-
nized by HCV1406 TCR-transduced T cells in a CD8-dependent
manner, whereas no recognition of the native MART-1 peptide
was observed (Fig. 6D). These results further demonstrate the
crucial importance of unique peptide features in determining
HCV1406 specificity, to include the p1 Lys “hot spot” and the
conformation of the peptide in the groove. Moreover, they re-
inforce how peptide features work together with the distinctive
surface chemistry of A2 in dictating the allospecific nature of the
HCV1406 TCR.
Discussion
The drivers of TCR alloreactivity have been variously attributed
to a TCR focus on unique allopeptides presented by allo-MHC
(peptide-centric) or to a TCR misfocus on polymorphic amino
acids on the α-helices of allo-MHC peptide-binding grooves
(MHC-centric) (37–39). The surprising specificity of many
alloreactive TCRs and structural studies of alloreactive complexes
have challenged these theories (3, 12, 13). Highly specific
alloreactive T cells and TCRs are being explored for targeting
what otherwise would be poorly immunogenic shared tumor anti-
gens and have been adopted for treatment of posttransplantation-
associated lymphoproliferative disease (4, 6, 7).
Here, we show that for the highly specific alloreactive TCR
HCV1406, recognition is both peptide- and MHC-centric, with
polymorphisms impacting how the TCR sees the MHC protein
as well as how the peptide is bound and presented. The structure
of the HCV1406–NS3/A2 complex revealed that the TCR en-
gages with a traditional binding mode, geometrically near the
limits but still within what has been observed for other TCR
complexes with A2. The TCR contacts polymorphic and non-
polymorphic sites along the α-helices of the A2-binding groove,
but does not focus solely on polymorphic sites, nor does it avoid
them. Of note are how the TCR interfaces with features that are
unique to A2, most notably the cluster of positive charge com-
posed of arginine at position 65 and lysine at position 66. Elec-
trostatic interactions with Arg65 and Lys66 are a characteristic
signature of TCRs that bind A2 (30), and changing Arg65 or
Lys66 to their counterparts in other human class I MHC proteins
disrupts receptor binding without impacting peptide binding.
Recognition is likewise influenced by other A2-distinctive fea-
tures, such as the collective identity of positions 62, 69, 76, and
79. Thus, binding of HCV1406 is dependent upon features that
distinguish the TCR-interacting surface of A2 from other MHC
proteins, both classical and nonclassical class I as well as class II.
As seen in other systems (33, 34), other polymorphic sites
within the A2 peptide-binding groove impact alloreactivity through
influences on peptide selection as well as peptide conformation.
Recognition also depends upon details of the NS3 peptide that
are not influenced by polymorphisms. The defining example is
the lysine at p1, which is engaged by residues of CDR1α and
whose replacement with alanine substantially weakens binding
and eliminates functional recognition.
Overall, the picture that emerges is that alloreactive recogni-
tion of NS3/A2 by HCV1406 is driven by three elements that,
together, define the composite peptide/MHC surface: (i) the
unique TCR contact surface of A2, including polymorphisms
that distinguish it from other MHC proteins that HCV1406 may
have encountered in its host; (ii) properties of the NS3 peptide
that are influenced by polymorphisms within the peptide-binding
groove; and (iii) structural and chemical properties of the NS3
peptide itself. Perturbation of any one of these elements alone is
sufficient to weaken receptor binding substantially.
These results explain the allospecific nature of HCV1406, but
are there lessons for alloreactivity in general? Our findings are
consistent with fundamental studies on TCR recognition show-
ing that TCR engagement of pMHC depends on unique surface
chemistries provided by both the peptide and MHC, whose
“roles” in binding are not easily separable (40). Our findings
therefore echo suggestions that at the molecular level, TCR
allorecognition is more “normal” than “abnormal” (3, 12). We
do not argue that more fully peptide- or MHC-centric alloreactivity
does not exist, but that perhaps we should not anticipate TCR
allorecognition to be unusually distinctive. If such is the case, our
results may also help explain the high frequency of alloreactive
T cells, because the combination of different surface chemistries
on allo-MHC, the influence of polymorphisms on peptide selec-
tion and conformation, and the presentation of unique peptides
collectively provide for recognition surfaces quite distinctive from
the recognition surfaces found syngeneically.
Our findings also offer perspectives on the determinants of
TCR MHC restriction. MHC restriction has been proposed to
emerge from the requirements for the CD4/CD8 coreceptors
during thymic selection and T-cell signaling (41). Our data make
it clear that if thymic education does select for MHC restriction,
it is sufficiently “fuzzy” to permit TCR engagement of allo-MHC
in standard geometries. Alloreactive TCRs such as HCV1406
that bind in standard geometries could underscore a need to
form a competent TCR–pMHC signaling complex that is structur-
ally compatible with the binding of coreceptor and/or CD3 signaling
units (42). There is evidence that such structural requirements do
Table 2. Impact of mutations at HLA-A2 polymorphic sites on
TCR and peptide binding
HLA-A2 variant Kd,* μM ΔΔG°,† kcal/mol Tm,‡ °C
Wild type 16 ± 1 63.5 ± 0.1
G62Q 100 ± 10 1.1 63.1 ± 0.2
G62R 164 ± 13 1.4 60.4 ± 0.3
R65Q nbd§ >2§ 62.6 ± 0.2
K66I >300¶ >2 63.2 ± 0.2
K66N >300¶ >2 63.2 ± 0.2
R65Q/K66I nbd >2 62.4 ± 0.1
A69R 154 ± 8 1.3 63.1 ± 0.3
V76E nbd >2 63.6 ± 0.1
G79R 77 ± 2 0.9 64.3 ± 0.1
H151R 15 ± 1 0 64.2 ± 0.1
V152E 46 ± 3 0.6 51.0 ± 0.2
V152W >300¶ >2 55.4 ± 0.2
nbd, no binding detected.
*Kd for TCR binding to pMHC measured by SPR. Errors are SDs from three
experiments.
†Change in binding free energy determined from ΔΔG° = RTln(Kd,mutant/
Kd,wild type).
‡Apparent Tm of the pMHC complex determined by DSF. Errors are SDs of
four experiments.
§Change in ΔΔG° is estimated at greater than 2 kcal/mol based on estab-
lished SPR measurement sensitivity (40).
¶Weak binding detected, but not quantifiable. Affinity is estimated at
>300 μM.
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exist: In one instance, a TCR–pMHC complex with a highly unusual
geometry did not signal (28), and, more recently, TCRs that bind
with reverse polarity have been shown to lead to poor T-cell
activation (26).
On the other hand, MHC restriction has been proposed to
emerge from an intrinsic bias of TCRs toward MHC proteins
(43), and there is evidence that TCR genes have coevolved with
genes of the MHC (44). Our observations of a traditional binding
mode with associated specificity could therefore reflect the in-
fluence of coevolved TCR-MHC contacts in binding. Indeed, the
HCV1406–NS3/A2 complex displays the hallmarks of TCRs that
bind A2, most notably the accommodation of the positive
charges on Arg65 and Lys66. We recently presented evidence
that, given the high frequency of A2 in human populations, the
need to offset this charge cluster has influenced the composition
of TCR genes, leading to biased recognition and restricted TCR
positioning (30). Therefore, although geometrical requirements
for coreceptor and CD3 compatibility could influence HCV1406
binding, the complex displays features associated with TCR-
MHC coevolution and a subsequent inherent bias of TCRs for
MHC proteins.
The fact that we could generate an HCV1406 cross-reactive
peptide based not on the NS3 viral epitope but on the structural
properties of the unrelated MART-1 tumor epitope underscores
the importance of structural mimicry (as opposed to sequence
mimicry) in T-cell recognition, both natural and allo. The ob-
servation that HCV1406 can cross-react between the NS3 epi-
tope and a single amino acid variant of MART-1 may seem
coincidental: Of the billions of possible decameric peptides, why
would the well-studied MART-1 peptide be identified as the root
of a molecular mimic? First, we note that in the central regions,
MART-1 and NS3 are both rather featureless, lacking bulky or
polar/charged side chains. Second, the backbone conformations
of the peptides are nearly identical, which is not unusual with
9- and 10-mers bound to class I MHC proteins. Third, where the
peptides are most different (p1 Lys in NS3 and p1 Glu in MART-1)
is the exact region where substitutions have the greatest impact
and direct cross-recognition. HCV1406 cross-reactivity with a
modified MART-1 peptide therefore underscores the impor-
tance of hot spots in TCR specificity: The TCR engages a key
region of the peptide that most directly influences specificity,
restricting amino acid composition there but leaving other regions
open to more diversity (45, 46). Our observations illustrate how
hotspots can work alongside mimicry in directing TCR specificity/
cross-reactivity and reinforce how peptide features working along-
side the distinctive surface chemistry of allo-MHC can drive
allospecificity.
In conclusion, we have shown that the specificity of the HCV1406
TCR emerges from how the TCR engages the cooperative pMHC
surface, with MHC polymorphisms influencing receptor binding
directly via TCR-MHC contacts and indirectly via impacts on pep-
tide binding and conformation. These observations can explain the
paradox of TCR specificity in alloreactivity, and provide a structural
and molecular context for the use of alloreactive TCRs in immu-
notherapy. More generally, our observations sharpen the discussion
of how MHC restriction is achieved, and provide a clear example of
how a peptide hotspot combined with structural mimicry can drive
TCR cross-reactivity.
Methods
Cells, Media, and Reagents. The 293GP, PG13, T2, and Jurkat cell lines were
obtained from the American Type Culture Collection. The 293GP cells were
Fig. 6. Structural mimicry between the NS3 and MART-1 peptides. (A) De-
spite sequence differences, the MART-1 decamer peptide is a close structural
and chemical mimic of the NS3 peptide, as shown in this superimposition of
the MART-1 decamer from the MART-1/A2 complex onto the NS3 peptide in
the HCV1406–NS3/A2 complex. The clearest difference is with the lysine
(NS3) and glutamate (MART-1) at p1. (B) When the HCV1406 TCR is visual-
ized in the superimposition, the receptor would clearly accommodate the
MART-1 peptide. The only obvious incompatibility is the presence of gluta-
mate instead of lysine at position 1, which would introduce charge repulsion
with Glu34 of CDR1α, as shown with the red dashed line. (C) Consistent with
the structural predictions, in a direct binding experiment, HCV1406 recog-
nizes a variant of MART-1 with the p1 Glu substituted with lysine. No rec-
ognition was seen of the native MART-1 peptide, emphasizing the
importance of the p1 Lys. Binding to NS3 from Fig. 1 is shown as a dashed
line for comparison. (D) E1K-modified MART-1 peptide was also recognized
in a functional assay by HCV1406-transduced CD8+ T cells, as shown in this
titration assessing IFN-γ release.



























maintained inDMEMsupplementedwith10%FBS. ThePG13 cellsweremaintained
in Iscove’s DMEM supplemented with 10% FBS. The T2 and Jurkat cell lines were
maintained in RPMI medium 1640 supplemented with 10% FBS.
Generation of CD8+ Jurkat cells has been described previously (19, 47).
Briefly, a modified SAMEN retroviral vector containing full-length human
CD8 α and β, separated by an internal SRα promoter, and an internal ribosome
entry site/neor cassette was used to transduce cells. CD8+ cells were sorted for
high and uniform expression by FACS using anti–CD8-PerCP/Cy5.5 mAb
and maintained in RPMI medium 1640 supplemented with 10% FBS and
500 μg/mL G418.
Human T cells were derived from deidentified apheresis products from
normal, healthy donors, purchased from Key Biologics. Ficoll-Hypaque density
gradient centrifugation was used to isolate peripheral bloodmononuclear cells
(PBMCs). Activated T cells used for retroviral transduction were generated by
stimulating PBMCs with 50 ng/mL anti-CD3 mAb for 3 d in AIM-V medium
supplemented with 5% heat-inactivated pooled human AB serum, 300 IU/mL
recombinant human IL-2, and 100 ng/mL recombinant human IL-15.
As described in the original publication describing the HCV1406 TCR, HLA
typingwas performed using PCR amplificationwith sequence-specific primers
(21). The original publication did not list the B types, but they were recorded
at the time as HLA-B7 and HLA-B13.
Retroviral Transduction. Retroviral supernatants were prepared using a high-
titer stable retroviral producer cell line, PG13, expressing HCV1406 TCR in a
modified SAMEN retroviral vector. Retroviral vectors contained the TCR
α-chain linked to the TCR β-chain and a truncated CD34 molecule by P2A and
T2A self-cleaving sequences, respectively. Generation of these stable pro-
ducer cell lines and collection of retrovirus have been described previously
(20, 22).
Jurkat cells, CD8+ Jurkat cells, and anti–CD3-activated primary T cells were
transduced to express HCV1406 TCR via spinoculation, as previously de-
scribed (20, 22, 47, 48). Briefly, 0.5 mL per well of 30 μg/mL retronectin was
used to coat 24-well, flat-bottom, nontissue culture-treated plates overnight
at 4 °C. The next day, plates were blocked with 0.5 mL per well of 2% PBSA
(PBS containing 2% BSA in PBS for 30 min at room temperature and washed
with 2 mL per well of PBS). Plates were loaded with 2 mL per well of filtered
retroviral supernatant, spun for 2 h at 2,000 × g at 32 °C, and gently aspi-
rated. Two million Jurkat cells in 1 mL of RPMI/10% FBS or 2 million OKT3-
activated T cells in 1 mL of AIM-V supplemented with 5% human immuno-
globulin monoclonal antibody (hAB), 600 IU/mL recombinant human IL-2 (rhIL-2),
and 200 ng/mL rhIL-15 were mixed with 1 mL per well of retroviral supernatant
and added to each well. The plates were spun again for 2 h at 2000 × g at 32 °C.
After 24 h, the transduced cells were harvested and transferred to tissue
culture-treated flasks. Three days later, the cells were analyzed for trans-
duction efficiency by FACS analysis using anti-CD34-phycoerythrin (PE) mAb.
T cells or Jurkat cells were then sorted for TCR-transduced cells by positive
selection using anti-CD34 mAb-coated immunomagnetic beads. TCR-
transduced T cells were also sorted into CD4+ or CD8+ fractions using anti-
CD4 and anti-CD8 mAb-coated immunomagnetic beads.
Immunofluorescence and Cytokine-Release Assays. HCV1406-TCR transduced
Jurkat cells and T cells were evaluated for transduction efficiency via im-
munofluorescence staining and quantified via flow cytometry as previously
described (20, 22). The mAbs used in these experiments were anti-CD3-APC/
Cy7, anti-CD4-PE/Cy7, anti-CD8-PerCP/Cy5.5, and anti-CD34-PE. Flow cytom-
etry was performed using a Canto II flow cytometer, and data were analyzed
with FlowJoX (FlowJo, LLC).
Antigen reactivity by HCV1406 TCR-transduced T cells and Jurkat cells
against peptide-loaded T2 cells was assessed by cytokine release assays as
previously described (49). Briefly, T2 cells were pulsed with 10 μg/mL peptide
for 2 h. For peptide titrations, T2 cells were pulsed with peptide concen-
trations ranging from 10–0.001 μg/mL. Target T2 (1 × 105) cells and effector
(TCR-transduced T cells or Jurkat; 1 × 105) cells were cocultured in a 1:1 ratio
in 96-well, U-bottom, tissue culture plates in 200 μL of RPMI 1640 supple-
mented with 10% FBS. Phorbol 12-myristate 13-acetate (10 ng/mL) was
added to Jurkat cell cocultures to enhance sensitivity of stimulation as de-
scribed elsewhere (20, 22). Cocultures were incubated at 37 °C overnight,
supernatants were harvested, and the amount of IFN-γ or IL-2 released by
1 × 105 T cells or Jurkat cells, respectively, was measured by ELISA.
Peptides and Proteins. Soluble pMHC and TCR were refolded from bacterially
expressed inclusion bodies following established procedures (50). Briefly,
isolated inclusion bodies of HLA-A2 heavy chain, β2m, TCR α-chain, and TCR
β-chain were dissolved in 8 M urea. For MHC refolding, HLA-A2 heavy chain
and β2m were diluted into MHC refolding buffer containing 100 mM Tris·HCl
(pH 8.3), 400 mM L-arginine, 6.3 mM cysteamine, 3.7 mM cystamine, 2 mM EDTA,
and 0.2 mM PMSF at a 1:3 molar ratio with excess peptide. For the TCR, α-chains
and β-chains were diluted into 50 mM Tris·HCl (pH 8.3), 2.5 M urea, 6.3 mM
cysteamine, 3.7 mM cystamine, 2 mM EDTA, and 0.2 mM PMSF with a 20%
excess of α-chain. After incubation for 12 h at 4 °C with constant stirring, the
mixtures were dialyzed against 10 mM Tris·HCl (pH 8.3) for 48 h. Refolded
complexes were purified with anion exchange chromatography followed by size
exclusion chromatography. Peptides were synthesized commercially by Synthetic
Biomolecules or Genscript, and were obtained at 95% purity. Mutations in the
HLA-A2 heavy chain were made using PCR-based mutagenesis.
Peptide-binding predictions were performed using the Immune Epitope
Database analysis resource Consensus tool (32) which combines predictions
from ANN (51–53), SMM (54), and Comblib (55). HLA sequences were com-
pared using data from the IMGT database (56).
Protein Crystallization, Data Collection, Structure Refinement, and Analysis.
Crystals of the HCV1406–NS3/A2 complex were grown in 13% vol/vol PEG
3350, 0.1 M sodium cacodylate (pH 6.1), 0.2 M ammonia sulfate, and 3%wt/vol
1,5-diaminopentane dihydrochloride at a protein concentration of 6 mg/mL at
20 °C. Crystallization was performed by hanging drop vapor diffusion. For cry-
oprotection, crystals were transferred into 20% glycerol/80% mother liquor for
30 s and immediately frozen in liquid nitrogen. Diffraction data were collected at
the 22ID SERCAT beamline at the Advanced Photon Source (Argonne National
Laboratories). Data were indexed, integrated, and scaled with the program
XDS22. The complexes were solved by molecular replacement with Phaser (57)
using the Protein Database (PDB) ID codes 3QEU and 3MRM as search models
(58). Rigid body refinement followed by translation/libration/screw refinement
was performed with Phenix and Refmac5 (59, 60). The twinning law “-h, -k, l”
was determined by Xtriage and applied in the last round of refinement. Evalu-
ation of themodels and fitting to maps were performed with the program Coot.
The model was checked in WHATIF and MolProbity to evaluate the structure
during the refinement (61, 62). Atomic positioning was verified with a simulated
annealing composite OMIT map calculated in Phenix. Density for the α3-domain
of HLA-A2 was weak for both molecules in the asymmetrical unit, contributing
to greater than typical Ramachandran deviations. The structure has been de-
posited into the PDB with ID code 5JZI. Analysis of hydrogen bonds and van der
Waals contacts was performed with the PISA server, using a cutoff of 4 Å for
contacts (63). Solvent-accessible surface areas were calculated using Discovery
Studio with a probe radius of 1.4 Å. Superimpositions and modeling of clashes
and compatibility were performed with Discovery Studio. TCR crossing and in-
cident angles were calculated as previously described (64, 65).
SPR and DSF. Steady-state–binding experiments were performed on Biacore
3000 and T200 instruments in HBS-EP buffer containing 10 mM Hepes
(pH 7.4), 150 mM NaCl, 3 mM EDTA, and 0.005% surfactant P20. The
HCV1406 TCR was covalently coupled to a CM5 sensor chip via standard
amine coupling. Equilibrium-binding experiments were performed by
injecting 25 μL of pMHC at a flow rate of 5 μL·min−1 over the concentration
range of 0.5 to 200 μM. The responses at equilibrium were determined by av-
eraging the signal over the final 10 s of the injection and subtracting the re-
sponses from identical injections over a blank flow cell. Experiments were
performed at 25 °C. Data were processed with BiaEvaluation 4.1 and fit with
OriginPro using a 1:1 binding model. For each experiment, all injections were
repeated twice and the two datasets were fit globally (66). Each experiment was
performed in triplicate, and the results were averaged for reporting values
and errors.
DSF was performed as previously described (24), using an Applied Bio-
systems StepOnePlus RT-PCR instrument with the excitation and emission
wavelengths set to 587 nm and 607 nm, respectively. Protein was dialyzed in
10 mM Hepes (pH 7.4), 150 mM NaCl, 3 mM EDTA, and 0.005% surfactant
P20 at concentrations of 4 μM, 6 μM, 8 μM, and 10 μM. SYPRO orange (Invi-
trogen) was added at fivefold and 10-fold concentrations to each protein con-
centration with a total reaction volume of 20 μL. The temperature range
spanned 25–95 °C, with a scan rate of 1 °C·min−1. Data analysis was performed in
OriginPro 9.0. Apparent Tm values were determined from the first derivative of
the melting curve. The derivative curve was processed with the single-peak–fit-
ting algorithm in OriginPro, fitting the peak to a Bigaussian function. The ap-
parent Tm values were averaged for measurements at four concentrations. Errors
are reported as the SD of the four measurements.
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